nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2016 | Original Article – Cancer Research

Valproic acid (VPA) inhibits the epithelial–mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4

verfasst von: Xiaopeng Lan, Guoliang Lu, Chuanwei Yuan, Shaowei Mao, Wei Jiang, Yougen Chen, Xunbo Jin, Qinghua Xia

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purposes

The epithelial–mesenchymal transition (EMT) plays an important role in cancer metastasis. Previous studies have reported that valproic acid (VPA) suppresses prostate carcinoma (PCa) cell metastasis and down-regulates SMAD4 protein levels, which is the key molecule in TGF-β-induced EMT. However, the correlation between VPA and the EMT in PCa remains uncertain.

Methods

Markers of the EMT in PCa cells and xenografts were molecularly assessed after VPA treatment. The expression and mono-ubiquitination of SMAD4 were also analyzed. After transfection with plasmids that express SMAD4 or short hairpin RNA for SMAD4 down-regulation, markers of EMT were examined to confirm whether VPA inhibits the EMT of PCa cells through the suppression of SMAD4.

Results

VPA induced the increase in E-cadherin (p < 0.05), and the decrease in N-cadherin (p < 0.05) and Vimentin (p < 0.05), in PCa cells and xenografts. SMAD4 mRNA and protein levels were repressed by VPA (p < 0.05), whereas the level of mono-ubiquitinated SMAD4 was increased (p < 0.05). SMAD4 knockdown significantly increased E-cadherin expression in PC3 cells, but SMAD4 over-expression abolished the VPA-mediated EMT-inhibitory effect.

Conclusions

VPA inhibits the EMT in PCa cells via the inhibition of SMAD4 expression and the mono-ubiquitination of SMAD4. VPA could serve as a promising agent in PCa treatment, with new strategies based on its diverse effects on posttranscriptional regulation.

Abend A, Kehat I (2015) Histone deacetylases as therapeutic targets—from cancer to cardiac disease. Pharmacol Ther 147C:55–62CrossRef

Axelrod H, Pienta KJ (2014) Axl as a mediator of cellular growth and survival. Oncotarget 5(19):8188–8852CrossRef

Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226(9):2378–2390PubMedCrossRef

Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, Chen ST, Tai SK, Kuo ML, Yang MH (2013) Connective tissue growth factor activates pluripotency genes and mesenchymal–epithelial transition in head and neck cancer cells. Cancer Res 73(13):4147–4157PubMedCrossRef

Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65(1):105–142PubMedPubMedCentralCrossRef

Choi JY, Kim JH, Jo SA (2014) Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes. Biochemical and biophysical research communications 450(1):372–377PubMedCrossRef

Cincarova L, Zdrahal Z, Fajkus J (2013) New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs 22:1535–1547PubMedCrossRef

Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470(7333):269–273PubMedPubMedCentralCrossRef

Drabsch Y, ten Dijke P (2012) TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31(3–4):553–568PubMedCrossRef

Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136(1):123–135PubMedCrossRef

Dupont S, Inui M, Newfeld SJ (2012) Regulation of TGF-beta signal transduction by mono- and deubiquitylation of Smads. FEBS Lett 586(14):1913–1920PubMedPubMedCentralCrossRef

Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13(9):673–691PubMedCrossRef

Fattet L, Ay AS, Bonneau B, Jallades L, Mikaelian I, Treilleux I, Gillet G, Hesling C, Rimokh R (2013) TIF1gamma requires sumoylation to exert its repressive activity on TGFbeta signaling. J Cell Sci 126(Pt 16):3713–3723PubMedCrossRef

Fuxe J, Vincent T, Herreros AG (2010) Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 9(12):2363–2374PubMedCrossRef

Han RF, Li K, Yang ZS, Chen ZG, Yang WC (2014) Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells. Mol Med Rep 10(6):3211–3216PubMed

He Y, Huang C, Sun X, Long XR, Lv XW, Li J (2012) MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal 24(10):1923–1930PubMedCrossRef

Hesling C, Fattet L, Teyre G, Jury D, Gonzalo P, Lopez J, Vanbelle C, Morel AP, Gillet G, Mikaelian I, Rimokh R (2011) Antagonistic regulation of EMT by TIF1gamma and Smad4 in mammary epithelial cells. EMBO Rep 12(7):665–672PubMedPubMedCentralCrossRef

Hudak L, Tezeeh P, Wedel S, Makarevic J, Juengel E, Tsaur I, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA (2012) Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 72(16):1719–1735PubMedCrossRef

Jiang W, Zheng Y, Huang Z, Wang M, Zhang Y, Wang Z, Jin X, Xia Q (2014) Role of SMAD4 in the mechanism of valproic acid’s inhibitory effect on prostate cancer cell invasiveness. Int Urol Nephrol 46(5):941–946PubMedCrossRef

Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal transition. J Clin Investig 119(6):1420–1428PubMedPubMedCentralCrossRef

Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C (2009) Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol 144(3):332–341PubMedCrossRef

Kortenhorst MS, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA et al (2009) Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 8(4):802–808PubMedPubMedCentralCrossRef

Kotiyal S, Bhattacharya S (2014) Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 453(1):112–116PubMedCrossRef

Kwon KJ, Kim JN, Kim MK, Kim SY, Cho KS, Jeon SJ, Kim HY, Ryu JH, Han SY, Cheong JH, Ignarro LJ, Han SH, Shin CY (2013) Neuroprotective effects of valproic acid against hemin toxicity: possible involvement of the down-regulation of heme oxygenase-1 by regulating ubiquitin–proteasomal pathway. Neurochem Int 62(3):240–250PubMedCrossRef

Li GF, Qian TL, Li GS, Yang CX, Qin M, Huang J, Sun M, Han YQ (2012) Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res 11(1):77–86PubMedCrossRef

Li P, Yang R, Gao WQ (2014) Contributions of epithelial–mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer 13:55PubMedPubMedCentralCrossRef

Martin SK, Kamelgarn M, Kyprianou N (2014) Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol 2(1):15–26PubMedPubMedCentral

Omer D, Harari-Steinberg O, Buzhor E, Metsuyanim S, Pleniceanu O, Zundelevich A, Gal-Yam EN, Dekel B (2013) Chromatin-modifying agents reactivate embryonic renal stem/progenitor genes in human adult kidney epithelial cells but abrogate dedifferentiation and stemness. Cell Reprogram 15(4):281–292PubMedPubMedCentral

Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S et al (2013) Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS ONE 8(10):e76773PubMedPubMedCentralCrossRef

Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63(2):309–320PubMedPubMedCentralCrossRef

Shan Z, Feng-Nian R, Jie G, Ting Z (2012) Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev 13(8):3977–3982PubMedCrossRef

Shimmi O, Newfeld SJ (2013) New insights into extracellular and post-translational regulation of TGF-beta family signalling pathways. J Biochem 154(1):11–19PubMedPubMedCentralCrossRef

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29PubMedCrossRef

Slingerland M, Guchelaar HJ, Gelderblom H (2014) Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25(2):140–149PubMedCrossRef

Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial–mesenchymal transition in vivo. Mol Cancer Ther 9(12):3254–3266PubMedCrossRef

Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Phillip Koeffler H (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141–1149PubMedCrossRef

Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70(14):5649–5669PubMedPubMedCentralCrossRef

Tsai C, Leslie JS, Franko-Tobin LG, Prasnal MC, Yang T, Mackey LV, Fuselier JA, Coy DH, Liu M, Yu C, Sun L (2013) Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet 288(2):393–400PubMedCrossRef

Wang Y, Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30(9):603–611PubMedPubMedCentralCrossRef

Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA (2011) Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 28(5):479–491PubMedCrossRef

Xie F, Zhang Z, van Dam H, Zhang L, Zhou F (2014) Regulation of TGF-beta superfamily signaling by SMAD mono-ubiquitination. Cells 3(4):981–993PubMedPubMedCentralCrossRef

Yao D, Dai C, Peng S (2011) Mechanism of the mesenchymal–epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9(12):1608–1620PubMedCrossRef

Zhu ML, Kyprianou N (2010) Role of androgens and the androgen receptor in epithelial–mesenchymal transition and invasion of prostate cancer cells. FASEB J 24(3):769–777PubMedPubMedCentralCrossRef

Titel: Valproic acid (VPA) inhibits the epithelial–mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4
verfasst von: Xiaopeng Lan
Guoliang Lu
Chuanwei Yuan
Shaowei Mao
Wei Jiang
Yougen Chen
Xunbo Jin
Qinghua Xia
Publikationsdatum: 01.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2020-4

Springer Medizin

Valproic acid (VPA) inhibits the epithelial–mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4